...
机译:在患有Ino-Vate患者的患者中,替代昔突ozogamicin的肌胞嘧啶ozogamicin的疗效和安全分析
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of Medical Oncology/Hematologic MalignanciesDana‐Farber Cancer InstituteBoston;
Department of Internal MedicineUniversity of MünsterMünster Germany;
Department of Hematology/OncologyUniversity of ChicagoChicago Illinois;
Divisions of Hematology and OncologyStanford Cancer InstituteStanford California;
Department of MedicineGoethe UniversityFrankfurt Germany;
Division of Hematology/OncologyUniversity of California IrvineOrange California;
Pfizer IncGroton Connecticut;
Pfizer IncGroton Connecticut;
Pfizer IncGroton Connecticut;
Pfizer IncCambridge Massachusetts;
Department of Medical Oncology/Hematologic MalignanciesDana‐Farber Cancer InstituteBoston;
Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas;
acute lymphoblastic leukemia (ALL); elderly; inotuzumab ozogamicin; safety; veno‐occlusive disease (VOD);
机译:在患有Ino-Vate患者的患者中,替代昔突ozogamicin的肌胞嘧啶ozogamicin的疗效和安全分析
机译:在III in Ino-Vate试验中,在Inotuzumab ozogamicin治疗复发/难治性急性淋巴细胞白血病患者中的影响
机译:Inotuzumab ozogamicin与重复或难治性急性淋巴细胞白血病的护理标准:最终报告和长期生存从随机,第3阶段的Ino-Vate研究
机译:竞争内源性RNA网络的分析及III期急性淋巴细胞白血病患者预后预测
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:依托珠单抗ozogamicin与复发或难治性急性淋巴细胞白血病的治疗标准:来自INOVATE 3期随机研究的最终报告和长期生存随访
机译:在ino-Vate中患者中患者患者inotuzumab ozogamicin患者的疗效和安全分析